File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The development of anti-HIV-1 drugs

TitleThe development of anti-HIV-1 drugs
Authors
KeywordsHIV-1
AIDS
Antiretroviral drug
Antiretroviral therapy
Highly active antiretroviral therapy
Issue Date2010
PublisherYaoxue Xuebao. The Journal's web site is located at http://yxxb.periodicals.net.cn/default.html
Citation
Acta Pharmaceutica Sinica (Yaoxue Xuebao), 2010, v. 45 n. 2, p. 165-176 How to Cite?
AbstractHuman immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired immunodeficiency disease syndrome (AIDS). After over 26 years of efforts, there is still not a therapeutic cure or an effective vaccine against HIV/AIDS. The clinical management of HIV-1 infected people largely relies on antiretroviral therapy (ART). Although highly active antiretroviral therapy (HAART) has provided an effective way to treat AIDS patients, the huge burden of ART in developing countries, together with the increasing incidence of drug resistant viruses among treated people, calls for continuous efforts for the development of anti-HIV-1 drugs. Currently, four classes of over 30 licensed antiretrovirals (ARVs) and combination regimens of these ARVs are in use clinically including: reverse transcriptase inhibitors (RTIs) (e.g. nucleoside reverse transcriptase inhibitors, NRTIs; and non-nucleoside reverse transcriptase inhibitors, NNRTIs), protease inhibitors (PIs), integrase inhibitors and entry inhibitors (e.g. fusion inhibitors and CCR5 antagonists). Here, we intend to provide updated information of currently available antiretroviral drugs for ART to promote the development of novel anti-HIV-1 drugs.
Persistent Identifierhttp://hdl.handle.net/10722/125553
ISSN
2015 SCImago Journal Rankings: 0.214
References

 

DC FieldValueLanguage
dc.contributor.authorLu, XFen_HK
dc.contributor.authorChen, ZWen_HK
dc.date.accessioned2010-10-31T11:37:55Z-
dc.date.available2010-10-31T11:37:55Z-
dc.date.issued2010en_HK
dc.identifier.citationActa Pharmaceutica Sinica (Yaoxue Xuebao), 2010, v. 45 n. 2, p. 165-176en_HK
dc.identifier.issn0513-4870en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125553-
dc.description.abstractHuman immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired immunodeficiency disease syndrome (AIDS). After over 26 years of efforts, there is still not a therapeutic cure or an effective vaccine against HIV/AIDS. The clinical management of HIV-1 infected people largely relies on antiretroviral therapy (ART). Although highly active antiretroviral therapy (HAART) has provided an effective way to treat AIDS patients, the huge burden of ART in developing countries, together with the increasing incidence of drug resistant viruses among treated people, calls for continuous efforts for the development of anti-HIV-1 drugs. Currently, four classes of over 30 licensed antiretrovirals (ARVs) and combination regimens of these ARVs are in use clinically including: reverse transcriptase inhibitors (RTIs) (e.g. nucleoside reverse transcriptase inhibitors, NRTIs; and non-nucleoside reverse transcriptase inhibitors, NNRTIs), protease inhibitors (PIs), integrase inhibitors and entry inhibitors (e.g. fusion inhibitors and CCR5 antagonists). Here, we intend to provide updated information of currently available antiretroviral drugs for ART to promote the development of novel anti-HIV-1 drugs.en_HK
dc.languageengen_HK
dc.publisherYaoxue Xuebao. The Journal's web site is located at http://yxxb.periodicals.net.cn/default.htmlen_HK
dc.relation.ispartofYaoxue Xuebaoen_HK
dc.subjectHIV-1-
dc.subjectAIDS-
dc.subjectAntiretroviral drug-
dc.subjectAntiretroviral therapy-
dc.subjectHighly active antiretroviral therapy-
dc.subject.meshAcquired Immunodeficiency Syndrome - drug therapyen_HK
dc.subject.meshAnti-HIV Agents - chemistry - pharmacology - therapeutic useen_HK
dc.subject.meshHIV Fusion Inhibitors - chemistry - pharmacology - therapeutic useen_HK
dc.subject.meshHIV Infections - drug therapyen_HK
dc.subject.meshHIV Integrase Inhibitors - chemistry - pharmacology - therapeutic useen_HK
dc.subject.meshHIV Protease Inhibitors - chemistry - pharmacology - therapeutic useen_HK
dc.subject.meshHIV-1 - drug effectsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMolecular Structureen_HK
dc.subject.meshReverse Transcriptase Inhibitors - chemistry - pharmacology - therapeutic useen_HK
dc.titleThe development of anti-HIV-1 drugsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0513-4870&volume=45&issue=2&spage=165&epage=176&date=2010&atitle=The+development+of+anti-HIV-1+drugs-
dc.identifier.emailChen, ZW:zchenai@hkucc.hku.hken_HK
dc.identifier.authorityChen, ZW=rp00243en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid21348415-
dc.identifier.scopuseid_2-s2.0-77950946460en_HK
dc.identifier.hkuros181679en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77950946460&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume45en_HK
dc.identifier.issue2en_HK
dc.identifier.spage165en_HK
dc.identifier.epage176en_HK
dc.publisher.placeChinaen_HK
dc.identifier.scopusauthoridLu, XF=35215493700en_HK
dc.identifier.scopusauthoridChen, ZW=35271180800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats